Genovis AB (publ.) (GENO.ST) fair value

ACCE thesis

Genovis sells enzyme-based tools, most notably the Cysteine Protease and Glycosidase families, that life science labs and biopharma manufacturers use to cut, trim and characterise proteins during drug development. The moat is the combination of proprietary enzyme discovery, an 88.6% gross margin that shows how little of each sale goes to cost of goods, and a consumables-style revenue base that recurs as customers move programmes from research into manufacturing. Revenue growth of 18.9% is the number to watch, with operating margin of 9.4% showing the company is still reinvesting heavily before scale shows up in the bottom line. At a trailing P/E of 68.0 and a forward P/E of 43.4, the market is already pricing in a meaningful step-up in earnings, so the case rests on whether margins expand as the installed base grows. Return on equity of 7.5% is thin for now, and the stock has no index membership, which limits passive demand. This is worth a deeper look to test the margin trajectory and the durability of the 18.9% growth rate.